We recently shared insights on the burgeoning weight-loss drug market in a Livewire article, highlighting global equities opportunities in this space.
As a global equities fund, we closely monitor emerging trends that could reshape investment landscapes. The article discusses the rapid growth of GLP-1 injectables like Ozempic and Wegovy, with projections suggesting the obesity drug market could reach $150 billion by 2030.
Key players like Novo Nordisk and Eli Lilly have seen significant stock movements amidst supply challenges and increased competition. The potential for 150 million users globally by 2030 underscores the significant market opportunity.
The article notes that "nearly 20 million people globally are now using" these drugs, equivalent to almost the population of Australia. We're particularly interested in how this trend might influence related sectors and create new investment opportunities. Our team continues to evaluate such trends for their impact on global equities strategies, always seeking to identify promising areas for potential investment.
To read the article, click the link below.